Aerovate reports 2023 net loss $75.5M; Phase 2b topline data for AV-101 in PAH expected June 2024

Jade Biosciences, Inc.

Cash, cash equivalents and short-term investments totaled $122.4M at Dec 31, 2023; cash runway expected into 2026.
Net loss for 2023 was $75.5M compared to $51.5M in 2022; R&D expenses rose to $64.2M from $38.6M.
Phase 2b portion of IMPAHCT trial enrolled 202 patients; topline data expected in June 2024.
First patient enrolled in Phase 3 portion of IMPAHCT in November 2023; over 120 clinical sites participating.
Board expanded with Habib Dable and Donald Santel; Dable appointed Chair in March 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Jade Biosciences, Inc. reported the year ended December 31, 2023 results: net income $75.5 million.

Period: the year ended December 31, 2023
Net income: $75.5 million
Result: reported results

Exact text from the filing

Net loss for the year ended December 31, 2023 was $75.5 million as compared to $51.5 million for the year ended December 31, 2022.

View on SEC.gov

1049 earnings releases filed in the last 30 days. Browse all earnings releases →

Jade Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001798749-24-000014

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.